Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
enGene Holdings Inc. Warrants (ENGNW)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
03/27/2025: ENGNW (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Moderate Performance
These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.
Analysis of Past Performance
Type Stock | Historic Profit 2.9% | Avg. Invested days 39 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 03/27/2025 |
Key Highlights
Company Size ETF | Market Capitalization 0 USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) 18206 | Beta -0.37 | 52 Weeks Range 0.42 - 4.89 | Updated Date 03/18/2025 |
52 Weeks Range 0.42 - 4.89 | Updated Date 03/18/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) - |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -25.75% | Return on Equity (TTM) -44.21% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value - | Price to Sales(TTM) - |
Enterprise Value - | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding - | Shares Floating 24461582 |
Shares Outstanding - | Shares Floating 24461582 | ||
Percent Insiders - | Percent Institutions - |
Analyst Ratings
Rating - | Target Price - | Buy - | Strong Buy - |
Buy - | Strong Buy - | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
enGene Holdings Inc. Warrants
Company Overview
History and Background
enGene Holdings Inc. is a clinical-stage genetic medicines company focused on developing gene therapies. Its warrants represent the right to purchase shares of enGene's common stock at a specific price and time. The company was founded with the goal of developing innovative gene therapies for various diseases.
Core Business Areas
- Gene Therapy Development: Research, development, and clinical testing of gene therapies targeting cancer and other diseases.
Leadership and Structure
The company has an executive leadership team and a board of directors. Specific details on individuals can be found on enGene's investor relations website.
Top Products and Market Share
Key Offerings
- EG-70: enGene's lead product candidate, EG-70, is an investigational gene therapy being developed for the treatment of high-risk, BCG-unresponsive non-muscle invasive bladder cancer (NMIBC). This is still in clinical trials, so no market share data or revenue is currently available. Competitors in NMIBC include FerGene's Adstiladrin and Merck's Keytruda.
Market Dynamics
Industry Overview
The gene therapy market is rapidly growing, driven by advancements in technology and increasing investment in the field. Significant unmet medical needs are driving the demand for novel therapies.
Positioning
enGene is positioning itself as a leader in the development of non-viral gene therapies. Their focus is on utilizing their non-viral platform to develop therapies for a range of diseases.
Total Addressable Market (TAM)
The gene therapy market is expected to reach billions of dollars in the coming years. enGene's addressable market depends on the successful development and approval of their therapies and the specific indications they target.
Upturn SWOT Analysis
Strengths
- Novel non-viral gene therapy platform
- Focus on unmet medical needs
- Experienced management team
Weaknesses
- Clinical trial risk
- Reliance on EG-70
- Limited financial resources compared to larger pharmaceutical companies
Opportunities
- Positive clinical trial results
- Partnerships with larger pharmaceutical companies
- Expansion into new disease areas
Threats
- Competition from other gene therapy companies
- Regulatory hurdles
- Adverse events in clinical trials
Competitors and Market Share
Key Competitors
- MRK
- ADVM
- BLUE
Competitive Landscape
enGene is a smaller company compared to some of its competitors, but it has a novel technology platform. Its success depends on differentiating itself through clinical efficacy and safety.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: enGene's growth is tied to the progression of its clinical programs. There has been limited historical growth due to the company being in the development stage.
Future Projections: Future growth is contingent on the success of clinical trials, regulatory approvals, and commercialization of EG-70 and other pipeline candidates. Analyst estimates vary and are subject to change.
Recent Initiatives: Focus on advancing EG-70 through clinical trials, exploring new indications, and seeking partnerships.
Summary
enGene is a clinical-stage company with a promising non-viral gene therapy platform. The company's success is heavily reliant on the clinical trial outcomes of EG-70 and its ability to secure funding. While the gene therapy market offers significant opportunities, enGene faces substantial risks associated with clinical development and competition.
Similar Companies
ADVM
Adverum Biotechnologies Inc
ADVM
Adverum Biotechnologies Inc
BLUE
Bluebird bio Inc
BLUE
Bluebird bio Inc
CRSP
Crispr Therapeutics AG
CRSP
Crispr Therapeutics AG
Sources and Disclaimers
Data Sources:
- enGene Holdings Inc. Investor Relations
- SEC Filings
- Industry Reports
- Analyst Reports
Disclaimers:
The information provided is for informational purposes only and does not constitute financial advice. Investment decisions should be made based on individual research and consultation with a qualified financial advisor. Market share data are estimated and may not be precise.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About enGene Holdings Inc. Warrants
Exchange NASDAQ | Headquaters Montreal, QC, Canada | ||
IPO Launch date 2023-11-01 | President, CEO & Director Mr. Ronald H. W. Cooper | ||
Sector Healthcare | Industry Biotechnology | Full time employees 56 | Website https://www.engene.com |
Full time employees 56 | Website https://www.engene.com | ||
enGene Holdings Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company that develops genetic medicines to help patients suffering from bladder cancer. Its lead product candidate is detalimogene voraplasmid, a non-viral monotherapy to treat non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) in patients that have been unresponsive to treatment with Bacillus Calmette-Guérin (BCG). enGene Holdings Inc. is based in Montreal, Canada.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.